Novartis Ag (NVS) Short term Debt (2016 - 2025)
Historic Short term Debt for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $5.6 billion.
- Novartis Ag's Short term Debt fell 3194.85% to $5.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 billion, marking a year-over-year decrease of 3194.85%. This contributed to the annual value of $5.6 billion for FY2025, which is 3194.85% down from last year.
- According to the latest figures from Q4 2025, Novartis Ag's Short term Debt is $5.6 billion, which was down 3194.85% from $7.5 billion recorded in Q3 2025.
- In the past 5 years, Novartis Ag's Short term Debt ranged from a high of $10.2 billion in Q1 2021 and a low of $5.5 billion during Q3 2023
- Over the past 5 years, Novartis Ag's median Short term Debt value was $7.3 billion (recorded in 2022), while the average stood at $7.4 billion.
- Per our database at Business Quant, Novartis Ag's Short term Debt tumbled by 3566.68% in 2021 and then soared by 3331.17% in 2024.
- Novartis Ag's Short term Debt (Quarter) stood at $6.3 billion in 2021, then fell by 5.78% to $5.9 billion in 2022, then grew by 4.11% to $6.2 billion in 2023, then surged by 33.31% to $8.2 billion in 2024, then crashed by 31.95% to $5.6 billion in 2025.
- Its Short term Debt stands at $5.6 billion for Q4 2025, versus $7.5 billion for Q3 2025 and $8.3 billion for Q2 2025.